SlideShare a Scribd company logo

PRECISE EARLY DETECTION OF LUNG CANCER AND IMMUNE CIRCUIT

Oleg Kshivets
Oleg Kshivets
Oleg Kshivetsthoracic/abdominal/general surgeon & surgical oncologist at Siauliai Public Hospital

PRECISE EARLY DETECTION OF LUNG CANCER AND IMMUNE CIRCUIT

PRECISE EARLY DETECTION OF LUNG CANCER AND IMMUNE CIRCUIT

1 of 2
Download to read offline
PRECISE EARLY DETECTION OF LUNG CANCER AND IMMUNE CIRCUIT
Oleg Kshivets
Kaluga Cancer Center, Russia,
nd SSO Annual Cancer Symposium, March 12-16, 2014, Phoenix, AZ, the USA
67
Bootstrap Simulation: n=450

Number of Samples=3333

Early Lung Cancer=48; Norm=120;

Kendall Tau-A

Error=0.0: Area Under ROC Curve=1.0; n=450):

P<

Rank Sensitivit
y

Monocytes

Rank

Neural Networks Simulation (Correct Classification=100%;

1

1496.65

Objective: Significance of immune circuit in terms of early detection of lung cancer (LC) was inestigated.

Non-Malignant Pathology =282

Methods: In trial (1987-2013) consecutive cases after surgery, monitored 48 LC patients (LCP) (m=40, f=8;
lobectomies=48) with pathologic stage IA (tomor size=1.6±0.4 cm; squamous=21, adenocarcinoma=25,
large cell=2; T1N0M0=48; G1=16, G2=21, G3=11, 5-year survival=100%), 282 patients with lung nonmalignant pathology (NMP) (m=188, f=94; pneumonectomies=5, lobectomies=179, segmentectomies=98;
non-malignant tumors=100; abscess=112; tuberculoma=70) and 120 healthy donors (HD) (m=69, f=51)
were reviewed.
Variables selected for study were input levels of immunity blood parameters, sex, age, TNMG. Thawed
aliquoted samples were evaluated for IgG, IgM, IgA, natural antibodies, circulating immune complexes.
The percentage, absolute count and total population number (per human organism) of T-lymphocytes
(CD3), B-lymphocytes (CD19), helper T-lymphocytes (CD4), suppressor/cytotoxic T-lymphocytes (CD8),
killer cells (O-cells, K-cells or CD16), precursor T-cells (CD1), activated T-cells (CDw26), monocytes (CD64,
CD13), helper/inducer T-lymphocytes (CD4+2H), contrsuppressor T-lymphocytes (CD8+VV), CD4/CD8,
leukocytes, lymphocytes, polymorphonuclear and sticknuclear leukocytes were estimated. The laboratory
blood studies also included input levels of NST (tests of oxygen dependent metabolism of neutrophils
spontaneous and stimulated by Staphylococcus aureus or by Streptococcus pyogenes), index of
stimulation of leukocytes by Staphylococcus aureus or Streptococcus pyogenes, index of thymus
function, phagocytic number, phagocyte index, index of complete phagocytosis.
Differences between groups were evaluated using discriminant analysis, clustering, nonlinear
estimation, structural equation modeling, Monte Carlo, bootstrap simulation and neural networks
computing.

B-Cells

1

-0.041

0.05

CD4+2H+Cells

2

1369.02

Segmented Neutrophils

2

-0.041

0.05

B-cells

3

1354.34

Leucocytes

3

-0.040

0.05

CD8+VV+Cells

4

1340.32

CD8+VV+Cells

4

-0.034

0.05

CD4+Cells

5

545.32

Monocytes

5

-0.028

0.05
CD16+Cells

6

348.67

Results: It was revealed that early detection of LC from NMP and HD (n=402) significantly depended on:
CD4+2H, CD8+VV, CD4, B, CD16, monocytes (P=0.017-0.000).
Neural networks computing, genetic algorithm selection and bootstrap simulation revealed
relationships of early detection of LC and monocytes (rank=1), CD4+2H (rank=2), CD19 (3), CD8+VV (4),
CD4 (5), CD16 (6).
Correct detection of early LCP was 100% by neural networks computing (error=0.000; area under ROC
curve=1.0).

P=0.023

T

P

r^2=0.039149654 DF Adj r^2=0.019495897 FitStdErr=0.30565814 Fstat=2.246057
a=0.64898982 b=0.19674838 c=-0.060515312 d=0.0044941272 e=-9.6163077e-05
f=0.10192687 g=-0.018714273 h=0.0012173861 i=-2.3777096e-05

-2.70302

0.007132

Monocytes

-3.07382

0.002242

B-cells

-4.32866

0.000019

CD16+cells

-2.23547

0.025879

CD8+VV+cells

-2.09551

-2.94928

1
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
17.5 15 2.5 0
1
1 7.5
T-Cells

5 2.5

1
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
15 0
10 12.5
ls
5 7.5
+Cel
2.5
8+VV
0 0
CD

0.036687

Leucocytes

Early Cancer---NMP, HD

Segmented Neutrophils

Early Cancer---NMP, HD

Significant Factors:

z=a+b/x+c/x^2+d/x^3+e/x^4+fy+gy^2+hy^3+iy^4

0.003352

Discriminant Function Analysis Summary No. of vars in model: 10; Wilks' Lambda:
.89179 approx. F (10,439)=5.3266 p< .0000
Wilks' - Lambda

P

CD4+Cells

0.902078

0.024945

CD8+VV+Cells

0.902549

0.021866

CD4+2H+Cells

0.903516

0.016712

B-Cells

0.939965

0.000002

T-Cells

0.909554

0.003277

Monocytes

0.910621

0.002473

Lymphocytes

0.905700

0.009192

Stimulation Index by Staphylococcus aureus

0.903661

0.016058

NST stimulated by Staphylococcus aureus

0.907671

0.005407

NST spontaneous

0.901417

0.030056

Poster #331
PRECISE EARLY DETECTION OF LUNG CANCER AND IMMUNE CIRCUIT
Oleg Kshivets

Conclusion: Early detection of LC from NMP and HD significantly depended on immune cell circuit.

Poster #331

Recommended

Kshivets iaslc toronto2018
Kshivets iaslc toronto2018Kshivets iaslc toronto2018
Kshivets iaslc toronto2018Oleg Kshivets
 
Kshivets barcelona2019
Kshivets barcelona2019Kshivets barcelona2019
Kshivets barcelona2019Oleg Kshivets
 
Kshivets iaslc denver2015
Kshivets iaslc denver2015Kshivets iaslc denver2015
Kshivets iaslc denver2015Oleg Kshivets
 
Kshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer SurgeryKshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer SurgeryOleg Kshivets
 
Kshivets iaslc denver2021
Kshivets iaslc denver2021Kshivets iaslc denver2021
Kshivets iaslc denver2021Oleg Kshivets
 
Kshivets IASLC_Vienna2016
Kshivets IASLC_Vienna2016Kshivets IASLC_Vienna2016
Kshivets IASLC_Vienna2016Oleg Kshivets
 
Lung Cancer: 10-Year Survival
Lung Cancer: 10-Year Survival           Lung Cancer: 10-Year Survival
Lung Cancer: 10-Year Survival Oleg Kshivets
 

More Related Content

What's hot

Kshivets iaslc singapore2020
Kshivets iaslc singapore2020Kshivets iaslc singapore2020
Kshivets iaslc singapore2020Oleg Kshivets
 
Kshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer SurgeryKshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer SurgeryOleg Kshivets
 
Kshivets Hong Kong Sydney2020
Kshivets Hong Kong Sydney2020Kshivets Hong Kong Sydney2020
Kshivets Hong Kong Sydney2020Oleg Kshivets
 
Kshivets aats new_york2018
Kshivets aats new_york2018Kshivets aats new_york2018
Kshivets aats new_york2018Oleg Kshivets
 
2021 esmo world_gi_poster_kshivets
2021 esmo world_gi_poster_kshivets2021 esmo world_gi_poster_kshivets
2021 esmo world_gi_poster_kshivetsOleg Kshivets
 
Kshivets barcelona2016
Kshivets barcelona2016Kshivets barcelona2016
Kshivets barcelona2016Oleg Kshivets
 
Kshivets O. Lung Cancer: Early Detection and Diagnosis
Kshivets O. Lung Cancer: Early Detection and Diagnosis Kshivets O. Lung Cancer: Early Detection and Diagnosis
Kshivets O. Lung Cancer: Early Detection and Diagnosis Oleg Kshivets
 
Kshivets aats new_york2019
Kshivets aats new_york2019Kshivets aats new_york2019
Kshivets aats new_york2019Oleg Kshivets
 
Kshivets wscts2019 sofia
Kshivets wscts2019 sofiaKshivets wscts2019 sofia
Kshivets wscts2019 sofiaOleg Kshivets
 
Kshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer SurgeryKshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer SurgeryOleg Kshivets
 
Kshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer SurgeryKshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer SurgeryOleg Kshivets
 
Kshivets chicago2016
Kshivets chicago2016Kshivets chicago2016
Kshivets chicago2016Oleg Kshivets
 
Kshivets eacts milan2018
Kshivets eacts milan2018Kshivets eacts milan2018
Kshivets eacts milan2018Oleg Kshivets
 
Kshivets O. Lung Cancer Surgery: Prognosis
Kshivets O. Lung Cancer Surgery: PrognosisKshivets O. Lung Cancer Surgery: Prognosis
Kshivets O. Lung Cancer Surgery: PrognosisOleg Kshivets
 
Kshivets astana wscts2017
Kshivets astana wscts2017Kshivets astana wscts2017
Kshivets astana wscts2017Oleg Kshivets
 
Kshivets yokohama iaslc2017
Kshivets yokohama iaslc2017Kshivets yokohama iaslc2017
Kshivets yokohama iaslc2017Oleg Kshivets
 
Kshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer SurgeryKshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer SurgeryOleg Kshivets
 
Kshivets O. Cardioesophageal Cancer Surgery
Kshivets O. Cardioesophageal Cancer SurgeryKshivets O. Cardioesophageal Cancer Surgery
Kshivets O. Cardioesophageal Cancer SurgeryOleg Kshivets
 
Kshivets ASCO Chicago2020
Kshivets ASCO Chicago2020Kshivets ASCO Chicago2020
Kshivets ASCO Chicago2020Oleg Kshivets
 

What's hot (20)

Kshivets iaslc singapore2020
Kshivets iaslc singapore2020Kshivets iaslc singapore2020
Kshivets iaslc singapore2020
 
Kshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer SurgeryKshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer Surgery
 
Kshivets Hong Kong Sydney2020
Kshivets Hong Kong Sydney2020Kshivets Hong Kong Sydney2020
Kshivets Hong Kong Sydney2020
 
Kshivets aats new_york2018
Kshivets aats new_york2018Kshivets aats new_york2018
Kshivets aats new_york2018
 
2021 esmo world_gi_poster_kshivets
2021 esmo world_gi_poster_kshivets2021 esmo world_gi_poster_kshivets
2021 esmo world_gi_poster_kshivets
 
Kshivets barcelona2016
Kshivets barcelona2016Kshivets barcelona2016
Kshivets barcelona2016
 
Kshivets sso2013
Kshivets sso2013Kshivets sso2013
Kshivets sso2013
 
Kshivets O. Lung Cancer: Early Detection and Diagnosis
Kshivets O. Lung Cancer: Early Detection and Diagnosis Kshivets O. Lung Cancer: Early Detection and Diagnosis
Kshivets O. Lung Cancer: Early Detection and Diagnosis
 
Kshivets aats new_york2019
Kshivets aats new_york2019Kshivets aats new_york2019
Kshivets aats new_york2019
 
Kshivets wscts2019 sofia
Kshivets wscts2019 sofiaKshivets wscts2019 sofia
Kshivets wscts2019 sofia
 
Kshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer SurgeryKshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer Surgery
 
Kshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer SurgeryKshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer Surgery
 
Kshivets chicago2016
Kshivets chicago2016Kshivets chicago2016
Kshivets chicago2016
 
Kshivets eacts milan2018
Kshivets eacts milan2018Kshivets eacts milan2018
Kshivets eacts milan2018
 
Kshivets O. Lung Cancer Surgery: Prognosis
Kshivets O. Lung Cancer Surgery: PrognosisKshivets O. Lung Cancer Surgery: Prognosis
Kshivets O. Lung Cancer Surgery: Prognosis
 
Kshivets astana wscts2017
Kshivets astana wscts2017Kshivets astana wscts2017
Kshivets astana wscts2017
 
Kshivets yokohama iaslc2017
Kshivets yokohama iaslc2017Kshivets yokohama iaslc2017
Kshivets yokohama iaslc2017
 
Kshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer SurgeryKshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer Surgery
 
Kshivets O. Cardioesophageal Cancer Surgery
Kshivets O. Cardioesophageal Cancer SurgeryKshivets O. Cardioesophageal Cancer Surgery
Kshivets O. Cardioesophageal Cancer Surgery
 
Kshivets ASCO Chicago2020
Kshivets ASCO Chicago2020Kshivets ASCO Chicago2020
Kshivets ASCO Chicago2020
 

Similar to PRECISE EARLY DETECTION OF LUNG CANCER AND IMMUNE CIRCUIT

Kshivets_SPB_WSCTS2022Lung.pdf
Kshivets_SPB_WSCTS2022Lung.pdfKshivets_SPB_WSCTS2022Lung.pdf
Kshivets_SPB_WSCTS2022Lung.pdfOleg Kshivets
 
Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...
Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...
Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...Oleg Kshivets
 
Kshivets O. Esophageal and Cardioesophageal Cancer Surgery
Kshivets O. Esophageal and Cardioesophageal Cancer SurgeryKshivets O. Esophageal and Cardioesophageal Cancer Surgery
Kshivets O. Esophageal and Cardioesophageal Cancer SurgeryOleg Kshivets
 
Kshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer SurgeryKshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer SurgeryOleg Kshivets
 
Kshivets wscts2018 ljubljana
Kshivets wscts2018 ljubljanaKshivets wscts2018 ljubljana
Kshivets wscts2018 ljubljanaOleg Kshivets
 
Kshivets ASCVTS Moscow2018
Kshivets ASCVTS Moscow2018Kshivets ASCVTS Moscow2018
Kshivets ASCVTS Moscow2018Oleg Kshivets
 
Kshivets_IASLC_Singapore2023.pdf
Kshivets_IASLC_Singapore2023.pdfKshivets_IASLC_Singapore2023.pdf
Kshivets_IASLC_Singapore2023.pdfOleg Kshivets
 
Kshivets_SPB_WSCTS2022Eso.pdf
Kshivets_SPB_WSCTS2022Eso.pdfKshivets_SPB_WSCTS2022Eso.pdf
Kshivets_SPB_WSCTS2022Eso.pdfOleg Kshivets
 
Esophageal Cancer: Precise Prediction
Esophageal Cancer: Precise Prediction      Esophageal Cancer: Precise Prediction
Esophageal Cancer: Precise Prediction Oleg Kshivets
 
Immunotherapy innsclc2017 thoracicsurgeons
Immunotherapy innsclc2017 thoracicsurgeonsImmunotherapy innsclc2017 thoracicsurgeons
Immunotherapy innsclc2017 thoracicsurgeonsMauricio Lema
 
Integración de la inmunoterapia en NSCLC
Integración de la inmunoterapia en NSCLCIntegración de la inmunoterapia en NSCLC
Integración de la inmunoterapia en NSCLCMauricio Lema
 
dkNET Webinar: Leveraging Computational Strategies to Identify Type 1 Diabete...
dkNET Webinar: Leveraging Computational Strategies to Identify Type 1 Diabete...dkNET Webinar: Leveraging Computational Strategies to Identify Type 1 Diabete...
dkNET Webinar: Leveraging Computational Strategies to Identify Type 1 Diabete...dkNET
 
Kshivets barcelona2020
Kshivets barcelona2020Kshivets barcelona2020
Kshivets barcelona2020Oleg Kshivets
 
Automated hematology analyzer as a cost effective aid to screen and monitor s...
Automated hematology analyzer as a cost effective aid to screen and monitor s...Automated hematology analyzer as a cost effective aid to screen and monitor s...
Automated hematology analyzer as a cost effective aid to screen and monitor s...nisaiims
 
4-yr OS after 2nd-line Nivolumab, pooled analysis (based on Scott Antonia pre...
4-yr OS after 2nd-line Nivolumab, pooled analysis (based on Scott Antonia pre...4-yr OS after 2nd-line Nivolumab, pooled analysis (based on Scott Antonia pre...
4-yr OS after 2nd-line Nivolumab, pooled analysis (based on Scott Antonia pre...Mauricio Lema
 
Kshivets O. Local Advanced Lung Cancer Surgery
Kshivets O. Local Advanced Lung Cancer Surgery Kshivets O. Local Advanced Lung Cancer Surgery
Kshivets O. Local Advanced Lung Cancer Surgery Oleg Kshivets
 

Similar to PRECISE EARLY DETECTION OF LUNG CANCER AND IMMUNE CIRCUIT (20)

Kshivets_SPB_WSCTS2022Lung.pdf
Kshivets_SPB_WSCTS2022Lung.pdfKshivets_SPB_WSCTS2022Lung.pdf
Kshivets_SPB_WSCTS2022Lung.pdf
 
Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...
Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...
Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...
 
Kshivets O. Esophageal and Cardioesophageal Cancer Surgery
Kshivets O. Esophageal and Cardioesophageal Cancer SurgeryKshivets O. Esophageal and Cardioesophageal Cancer Surgery
Kshivets O. Esophageal and Cardioesophageal Cancer Surgery
 
Kshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer SurgeryKshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer Surgery
 
Kshivets esmo2021
Kshivets esmo2021Kshivets esmo2021
Kshivets esmo2021
 
Kshivets wscts2018 ljubljana
Kshivets wscts2018 ljubljanaKshivets wscts2018 ljubljana
Kshivets wscts2018 ljubljana
 
Kshivets ASCVTS Moscow2018
Kshivets ASCVTS Moscow2018Kshivets ASCVTS Moscow2018
Kshivets ASCVTS Moscow2018
 
Kshivets elcc2022
Kshivets elcc2022Kshivets elcc2022
Kshivets elcc2022
 
Kshivets_IASLC_Singapore2023.pdf
Kshivets_IASLC_Singapore2023.pdfKshivets_IASLC_Singapore2023.pdf
Kshivets_IASLC_Singapore2023.pdf
 
Kshivets_SPB_WSCTS2022Eso.pdf
Kshivets_SPB_WSCTS2022Eso.pdfKshivets_SPB_WSCTS2022Eso.pdf
Kshivets_SPB_WSCTS2022Eso.pdf
 
Esophageal Cancer: Precise Prediction
Esophageal Cancer: Precise Prediction      Esophageal Cancer: Precise Prediction
Esophageal Cancer: Precise Prediction
 
Immunotherapy innsclc2017 thoracicsurgeons
Immunotherapy innsclc2017 thoracicsurgeonsImmunotherapy innsclc2017 thoracicsurgeons
Immunotherapy innsclc2017 thoracicsurgeons
 
Integración de la inmunoterapia en NSCLC
Integración de la inmunoterapia en NSCLCIntegración de la inmunoterapia en NSCLC
Integración de la inmunoterapia en NSCLC
 
dkNET Webinar: Leveraging Computational Strategies to Identify Type 1 Diabete...
dkNET Webinar: Leveraging Computational Strategies to Identify Type 1 Diabete...dkNET Webinar: Leveraging Computational Strategies to Identify Type 1 Diabete...
dkNET Webinar: Leveraging Computational Strategies to Identify Type 1 Diabete...
 
PlOSone paper
PlOSone paperPlOSone paper
PlOSone paper
 
Kshivets barcelona2020
Kshivets barcelona2020Kshivets barcelona2020
Kshivets barcelona2020
 
Kshivets ny2021aats
Kshivets ny2021aatsKshivets ny2021aats
Kshivets ny2021aats
 
Automated hematology analyzer as a cost effective aid to screen and monitor s...
Automated hematology analyzer as a cost effective aid to screen and monitor s...Automated hematology analyzer as a cost effective aid to screen and monitor s...
Automated hematology analyzer as a cost effective aid to screen and monitor s...
 
4-yr OS after 2nd-line Nivolumab, pooled analysis (based on Scott Antonia pre...
4-yr OS after 2nd-line Nivolumab, pooled analysis (based on Scott Antonia pre...4-yr OS after 2nd-line Nivolumab, pooled analysis (based on Scott Antonia pre...
4-yr OS after 2nd-line Nivolumab, pooled analysis (based on Scott Antonia pre...
 
Kshivets O. Local Advanced Lung Cancer Surgery
Kshivets O. Local Advanced Lung Cancer Surgery Kshivets O. Local Advanced Lung Cancer Surgery
Kshivets O. Local Advanced Lung Cancer Surgery
 

More from Oleg Kshivets

KshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdfKshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdfOleg Kshivets
 
Kshivets_WCGIC2023.pdf
Kshivets_WCGIC2023.pdfKshivets_WCGIC2023.pdf
Kshivets_WCGIC2023.pdfOleg Kshivets
 
Kshivets gc 10_ys_wjarr-2021-0659
Kshivets gc 10_ys_wjarr-2021-0659Kshivets gc 10_ys_wjarr-2021-0659
Kshivets gc 10_ys_wjarr-2021-0659Oleg Kshivets
 
Kshivets lc10 ys_wjarr
Kshivets lc10 ys_wjarrKshivets lc10 ys_wjarr
Kshivets lc10 ys_wjarrOleg Kshivets
 
Kshivets eso10 y2021
Kshivets eso10 y2021Kshivets eso10 y2021
Kshivets eso10 y2021Oleg Kshivets
 
Combined Esophagogastrectomies: Survival Outcomes in Patients with Local Adva...
Combined Esophagogastrectomies: Survival Outcomes in Patients with Local Adva...Combined Esophagogastrectomies: Survival Outcomes in Patients with Local Adva...
Combined Esophagogastrectomies: Survival Outcomes in Patients with Local Adva...Oleg Kshivets
 

More from Oleg Kshivets (7)

KshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdfKshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdf
 
Kshivets_WCGIC2023.pdf
Kshivets_WCGIC2023.pdfKshivets_WCGIC2023.pdf
Kshivets_WCGIC2023.pdf
 
Kshivets gc 10_ys_wjarr-2021-0659
Kshivets gc 10_ys_wjarr-2021-0659Kshivets gc 10_ys_wjarr-2021-0659
Kshivets gc 10_ys_wjarr-2021-0659
 
Kshivets lc10 ys_wjarr
Kshivets lc10 ys_wjarrKshivets lc10 ys_wjarr
Kshivets lc10 ys_wjarr
 
Kshivets eso10 y2021
Kshivets eso10 y2021Kshivets eso10 y2021
Kshivets eso10 y2021
 
Combined Esophagogastrectomies: Survival Outcomes in Patients with Local Adva...
Combined Esophagogastrectomies: Survival Outcomes in Patients with Local Adva...Combined Esophagogastrectomies: Survival Outcomes in Patients with Local Adva...
Combined Esophagogastrectomies: Survival Outcomes in Patients with Local Adva...
 
Kshivets IASLC 2019
Kshivets IASLC 2019Kshivets IASLC 2019
Kshivets IASLC 2019
 

Recently uploaded

Cell cytoskeleton and molecular motors.pdf
Cell cytoskeleton and molecular motors.pdfCell cytoskeleton and molecular motors.pdf
Cell cytoskeleton and molecular motors.pdfMedicoseAcademics
 
TRANSPORT PROCESS ACROSS CELL MEMBRANE.pptx
TRANSPORT PROCESS ACROSS CELL MEMBRANE.pptxTRANSPORT PROCESS ACROSS CELL MEMBRANE.pptx
TRANSPORT PROCESS ACROSS CELL MEMBRANE.pptxPoojaDahale3
 
Tolerance Hydra10P Avene trainings blink
Tolerance Hydra10P Avene trainings blinkTolerance Hydra10P Avene trainings blink
Tolerance Hydra10P Avene trainings blinkClinicians
 
pediatrics. epilepsy and seizures in children 8.ppt
pediatrics. epilepsy and seizures in children 8.pptpediatrics. epilepsy and seizures in children 8.ppt
pediatrics. epilepsy and seizures in children 8.pptArun170190
 
Dental Hygiene Library session Searching - 2nd class
Dental Hygiene Library session Searching - 2nd classDental Hygiene Library session Searching - 2nd class
Dental Hygiene Library session Searching - 2nd classHVCClibrary
 
ANTI-HYPERTENSIVE DRUG - RAUWOLFIA ROOT.
ANTI-HYPERTENSIVE DRUG - RAUWOLFIA ROOT.ANTI-HYPERTENSIVE DRUG - RAUWOLFIA ROOT.
ANTI-HYPERTENSIVE DRUG - RAUWOLFIA ROOT.Divya Kanojiya
 
GLANDS IN THE SKIN,FUNCTIONS AND ABNORMALITIES ..pptx
GLANDS IN THE SKIN,FUNCTIONS AND ABNORMALITIES ..pptxGLANDS IN THE SKIN,FUNCTIONS AND ABNORMALITIES ..pptx
GLANDS IN THE SKIN,FUNCTIONS AND ABNORMALITIES ..pptxWINCY THIRUMURUGAN
 
skin diseases shaffer................ppt
skin diseases shaffer................pptskin diseases shaffer................ppt
skin diseases shaffer................pptHimanshu Goyal
 
Seminario BioMol- Aura Cristina Peña Santos
Seminario BioMol- Aura Cristina Peña SantosSeminario BioMol- Aura Cristina Peña Santos
Seminario BioMol- Aura Cristina Peña SantosAuraCristinaPeaSanto
 
The EMA and Glucagon-Like Peptide-1 Agonists: A Wake-Up Call
The EMA and Glucagon-Like Peptide-1 Agonists: A Wake-Up CallThe EMA and Glucagon-Like Peptide-1 Agonists: A Wake-Up Call
The EMA and Glucagon-Like Peptide-1 Agonists: A Wake-Up Callsemualkaira
 
Pott's Spine. (Tuberculosis Spine) pptx
Pott's Spine.  (Tuberculosis Spine) pptxPott's Spine.  (Tuberculosis Spine) pptx
Pott's Spine. (Tuberculosis Spine) pptxShashi Prakash
 
Epidemiological Study Design, Research Design, Clinical Research
Epidemiological Study Design, Research Design, Clinical ResearchEpidemiological Study Design, Research Design, Clinical Research
Epidemiological Study Design, Research Design, Clinical ResearchDr KHALID B.M
 
Cell locomotion (Ameboid/ciliary/flagellar movement)
Cell locomotion (Ameboid/ciliary/flagellar movement)Cell locomotion (Ameboid/ciliary/flagellar movement)
Cell locomotion (Ameboid/ciliary/flagellar movement)MedicoseAcademics
 
Presentation on Cerebral Palsy and its orthotic management
Presentation on Cerebral Palsy and its orthotic managementPresentation on Cerebral Palsy and its orthotic management
Presentation on Cerebral Palsy and its orthotic managementeshasmalik27
 
Target pain receptors with essential oils
Target pain receptors with essential oilsTarget pain receptors with essential oils
Target pain receptors with essential oilsKevin KF Ng
 
Peripheral Vascular Disease (PVD): Physiotherapy assessment and management
Peripheral Vascular Disease (PVD): Physiotherapy assessment and managementPeripheral Vascular Disease (PVD): Physiotherapy assessment and management
Peripheral Vascular Disease (PVD): Physiotherapy assessment and managementTushar Sharma
 
Appeptite stimulants and suppresents.pdf
Appeptite stimulants and suppresents.pdfAppeptite stimulants and suppresents.pdf
Appeptite stimulants and suppresents.pdfKoppala RVS Chaitanya
 

Recently uploaded (20)

Cell cytoskeleton and molecular motors.pdf
Cell cytoskeleton and molecular motors.pdfCell cytoskeleton and molecular motors.pdf
Cell cytoskeleton and molecular motors.pdf
 
TRANSPORT PROCESS ACROSS CELL MEMBRANE.pptx
TRANSPORT PROCESS ACROSS CELL MEMBRANE.pptxTRANSPORT PROCESS ACROSS CELL MEMBRANE.pptx
TRANSPORT PROCESS ACROSS CELL MEMBRANE.pptx
 
Tolerance Hydra10P Avene trainings blink
Tolerance Hydra10P Avene trainings blinkTolerance Hydra10P Avene trainings blink
Tolerance Hydra10P Avene trainings blink
 
pediatrics. epilepsy and seizures in children 8.ppt
pediatrics. epilepsy and seizures in children 8.pptpediatrics. epilepsy and seizures in children 8.ppt
pediatrics. epilepsy and seizures in children 8.ppt
 
Dental Hygiene Library session Searching - 2nd class
Dental Hygiene Library session Searching - 2nd classDental Hygiene Library session Searching - 2nd class
Dental Hygiene Library session Searching - 2nd class
 
ANTI-HYPERTENSIVE DRUG - RAUWOLFIA ROOT.
ANTI-HYPERTENSIVE DRUG - RAUWOLFIA ROOT.ANTI-HYPERTENSIVE DRUG - RAUWOLFIA ROOT.
ANTI-HYPERTENSIVE DRUG - RAUWOLFIA ROOT.
 
GLANDS IN THE SKIN,FUNCTIONS AND ABNORMALITIES ..pptx
GLANDS IN THE SKIN,FUNCTIONS AND ABNORMALITIES ..pptxGLANDS IN THE SKIN,FUNCTIONS AND ABNORMALITIES ..pptx
GLANDS IN THE SKIN,FUNCTIONS AND ABNORMALITIES ..pptx
 
skin diseases shaffer................ppt
skin diseases shaffer................pptskin diseases shaffer................ppt
skin diseases shaffer................ppt
 
Seminario BioMol- Aura Cristina Peña Santos
Seminario BioMol- Aura Cristina Peña SantosSeminario BioMol- Aura Cristina Peña Santos
Seminario BioMol- Aura Cristina Peña Santos
 
The EMA and Glucagon-Like Peptide-1 Agonists: A Wake-Up Call
The EMA and Glucagon-Like Peptide-1 Agonists: A Wake-Up CallThe EMA and Glucagon-Like Peptide-1 Agonists: A Wake-Up Call
The EMA and Glucagon-Like Peptide-1 Agonists: A Wake-Up Call
 
Pott's Spine. (Tuberculosis Spine) pptx
Pott's Spine.  (Tuberculosis Spine) pptxPott's Spine.  (Tuberculosis Spine) pptx
Pott's Spine. (Tuberculosis Spine) pptx
 
Epidemiological Study Design, Research Design, Clinical Research
Epidemiological Study Design, Research Design, Clinical ResearchEpidemiological Study Design, Research Design, Clinical Research
Epidemiological Study Design, Research Design, Clinical Research
 
Cell locomotion (Ameboid/ciliary/flagellar movement)
Cell locomotion (Ameboid/ciliary/flagellar movement)Cell locomotion (Ameboid/ciliary/flagellar movement)
Cell locomotion (Ameboid/ciliary/flagellar movement)
 
Presentation on Cerebral Palsy and its orthotic management
Presentation on Cerebral Palsy and its orthotic managementPresentation on Cerebral Palsy and its orthotic management
Presentation on Cerebral Palsy and its orthotic management
 
Expectorants and Antitussives.pdf
Expectorants and Antitussives.pdfExpectorants and Antitussives.pdf
Expectorants and Antitussives.pdf
 
Target pain receptors with essential oils
Target pain receptors with essential oilsTarget pain receptors with essential oils
Target pain receptors with essential oils
 
Introduction Endocrinology class -2.pptx
Introduction Endocrinology class -2.pptxIntroduction Endocrinology class -2.pptx
Introduction Endocrinology class -2.pptx
 
Peripheral Vascular Disease (PVD): Physiotherapy assessment and management
Peripheral Vascular Disease (PVD): Physiotherapy assessment and managementPeripheral Vascular Disease (PVD): Physiotherapy assessment and management
Peripheral Vascular Disease (PVD): Physiotherapy assessment and management
 
Anti-interferon-gamma autoantibody associated immunodeficiency
Anti-interferon-gamma autoantibody associated immunodeficiencyAnti-interferon-gamma autoantibody associated immunodeficiency
Anti-interferon-gamma autoantibody associated immunodeficiency
 
Appeptite stimulants and suppresents.pdf
Appeptite stimulants and suppresents.pdfAppeptite stimulants and suppresents.pdf
Appeptite stimulants and suppresents.pdf
 

PRECISE EARLY DETECTION OF LUNG CANCER AND IMMUNE CIRCUIT

  • 1. PRECISE EARLY DETECTION OF LUNG CANCER AND IMMUNE CIRCUIT Oleg Kshivets Kaluga Cancer Center, Russia, nd SSO Annual Cancer Symposium, March 12-16, 2014, Phoenix, AZ, the USA 67 Bootstrap Simulation: n=450 Number of Samples=3333 Early Lung Cancer=48; Norm=120; Kendall Tau-A Error=0.0: Area Under ROC Curve=1.0; n=450): P< Rank Sensitivit y Monocytes Rank Neural Networks Simulation (Correct Classification=100%; 1 1496.65 Objective: Significance of immune circuit in terms of early detection of lung cancer (LC) was inestigated. Non-Malignant Pathology =282 Methods: In trial (1987-2013) consecutive cases after surgery, monitored 48 LC patients (LCP) (m=40, f=8; lobectomies=48) with pathologic stage IA (tomor size=1.6±0.4 cm; squamous=21, adenocarcinoma=25, large cell=2; T1N0M0=48; G1=16, G2=21, G3=11, 5-year survival=100%), 282 patients with lung nonmalignant pathology (NMP) (m=188, f=94; pneumonectomies=5, lobectomies=179, segmentectomies=98; non-malignant tumors=100; abscess=112; tuberculoma=70) and 120 healthy donors (HD) (m=69, f=51) were reviewed. Variables selected for study were input levels of immunity blood parameters, sex, age, TNMG. Thawed aliquoted samples were evaluated for IgG, IgM, IgA, natural antibodies, circulating immune complexes. The percentage, absolute count and total population number (per human organism) of T-lymphocytes (CD3), B-lymphocytes (CD19), helper T-lymphocytes (CD4), suppressor/cytotoxic T-lymphocytes (CD8), killer cells (O-cells, K-cells or CD16), precursor T-cells (CD1), activated T-cells (CDw26), monocytes (CD64, CD13), helper/inducer T-lymphocytes (CD4+2H), contrsuppressor T-lymphocytes (CD8+VV), CD4/CD8, leukocytes, lymphocytes, polymorphonuclear and sticknuclear leukocytes were estimated. The laboratory blood studies also included input levels of NST (tests of oxygen dependent metabolism of neutrophils spontaneous and stimulated by Staphylococcus aureus or by Streptococcus pyogenes), index of stimulation of leukocytes by Staphylococcus aureus or Streptococcus pyogenes, index of thymus function, phagocytic number, phagocyte index, index of complete phagocytosis. Differences between groups were evaluated using discriminant analysis, clustering, nonlinear estimation, structural equation modeling, Monte Carlo, bootstrap simulation and neural networks computing. B-Cells 1 -0.041 0.05 CD4+2H+Cells 2 1369.02 Segmented Neutrophils 2 -0.041 0.05 B-cells 3 1354.34 Leucocytes 3 -0.040 0.05 CD8+VV+Cells 4 1340.32 CD8+VV+Cells 4 -0.034 0.05 CD4+Cells 5 545.32 Monocytes 5 -0.028 0.05 CD16+Cells 6 348.67 Results: It was revealed that early detection of LC from NMP and HD (n=402) significantly depended on: CD4+2H, CD8+VV, CD4, B, CD16, monocytes (P=0.017-0.000). Neural networks computing, genetic algorithm selection and bootstrap simulation revealed relationships of early detection of LC and monocytes (rank=1), CD4+2H (rank=2), CD19 (3), CD8+VV (4), CD4 (5), CD16 (6). Correct detection of early LCP was 100% by neural networks computing (error=0.000; area under ROC curve=1.0). P=0.023 T P r^2=0.039149654 DF Adj r^2=0.019495897 FitStdErr=0.30565814 Fstat=2.246057 a=0.64898982 b=0.19674838 c=-0.060515312 d=0.0044941272 e=-9.6163077e-05 f=0.10192687 g=-0.018714273 h=0.0012173861 i=-2.3777096e-05 -2.70302 0.007132 Monocytes -3.07382 0.002242 B-cells -4.32866 0.000019 CD16+cells -2.23547 0.025879 CD8+VV+cells -2.09551 -2.94928 1 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0 17.5 15 2.5 0 1 1 7.5 T-Cells 5 2.5 1 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 15 0 10 12.5 ls 5 7.5 +Cel 2.5 8+VV 0 0 CD 0.036687 Leucocytes Early Cancer---NMP, HD Segmented Neutrophils Early Cancer---NMP, HD Significant Factors: z=a+b/x+c/x^2+d/x^3+e/x^4+fy+gy^2+hy^3+iy^4 0.003352 Discriminant Function Analysis Summary No. of vars in model: 10; Wilks' Lambda: .89179 approx. F (10,439)=5.3266 p< .0000 Wilks' - Lambda P CD4+Cells 0.902078 0.024945 CD8+VV+Cells 0.902549 0.021866 CD4+2H+Cells 0.903516 0.016712 B-Cells 0.939965 0.000002 T-Cells 0.909554 0.003277 Monocytes 0.910621 0.002473 Lymphocytes 0.905700 0.009192 Stimulation Index by Staphylococcus aureus 0.903661 0.016058 NST stimulated by Staphylococcus aureus 0.907671 0.005407 NST spontaneous 0.901417 0.030056 Poster #331
  • 2. PRECISE EARLY DETECTION OF LUNG CANCER AND IMMUNE CIRCUIT Oleg Kshivets Conclusion: Early detection of LC from NMP and HD significantly depended on immune cell circuit. Poster #331